News
TipRanks on MSN5d
Klotho Neurosciences Receives FDA Orphan Drug DesignationKlotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...
News Medical on MSN8h
FDA grants orphan drug designation to UAB-developed gene therapy for ALSThe U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral ...
Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.
The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB).
KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and oxidative stress.
Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...
US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...
Asianet Newsable on MSN4d
Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene TherapyThe FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...
Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback